Eli Lilly had very little competition in its eventual deal for Ventyx Biosciences, one of the leading drug developers in the hot NLRP3 arena. The Indianapolis drug giant scooped up the San Diego biotech for …
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
